0.1046
7667766266
x

India’s Tuberculosis Challenge

iasparliament Logo
June 06, 2026

Mains: GS II | Governance

Why in News?

More than a century after the introduction of the Bacillus Calmette-Guérin (BCG) vaccine, Tuberculosis (TB) remains one of the world's deadliest infectious diseases, disproportionately impacting Low- and Middle-Income Countries (LMICs).

What is Tuberculosis (TB)?

  • Tuberculosis (TB) is a contagious airborne bacterial infection primarily affecting the lungs, though it can impact any part of the body.
  • Caused by - Mycobacterium tuberculosis.
  • Spread - The disease spreads when bacteria-carrying droplets are inhaled from an infected person's coughs, sneezes, or speech.
  • Symptoms - Symptoms depend on whether the infection is active or latent.
  • Latent TB - The bacteria live in the body but are inactive and asymptomatic, are not contagious, and may only test positive on a skin or blood test.
  • Active TB (Disease) - The bacteria multiply, make sick and contagious. 
  • Pulmonary TB - Is active TB that involves the lungs. When a Person contract it by breathing in air exhaled by someone who has TB. The germs can remain in the air for several hours.
  • Common signs - A persistent bad cough lasting more than 3 weeks Coughing up blood or mucus Chest pain or pain while breathing/coughing Unexplained fatigue and weight loss Drenching night sweats and fever
  • Treatment & Prevention - Though preventable and highly curable, active TB is fatal if left untreated.

India accounts for approximately 27% of global TB cases.

24th March is observed as World Tuberculosis Day. ( Click the link to Know More about TB)

What is India’s Need for a Layered Approach?

  • With TB incidence between 200–300 per 100,000 population, India faces one of the world’s highest burdens.
  • Reducing this to 10–20 per 100,000, the elimination threshold demands systemic reform.
  • India’s strategy must move beyond the pursuit of a perfect vaccine and adopt a layered approach
    • Early Detection – Strengthen diagnostics, including tools for subclinical TB.
    • Preventive Therapy – Treat latent infections before they progress.
    • Vaccination – Integrate new vaccines into national programs.

How does the PreVenTB Trial makes a Turning Point?

  • Recent findings from the ICMR-led PreVenTB trial, mark a milestone.
  • Conducted across 18 sites with over 12,700 participants, it evaluated 2 indigenous vaccines — VPM1002 (SIIPL) and Immuvac (Cadila).
  • VPM1002 - 50.4% efficacy against EPTB; 64.6% efficacy in children aged 6–14 years.
  • Immuvac - Over 60% efficacy against EPTB in children aged 6–10 years and latent infection progression.
  • These findings are significant, especially since no other global trial has evaluated efficacy against EPTB.

What are the Public Health and Ethical Dimensions?

  • Ethical Imperative of Action - Waiting for a perfect vaccine risk perpetuating preventable deaths.
  • Ethically, India must act on available evidence to protect vulnerable populations rather than delay intervention.
  • Equity and Nutrition - Reduced efficacy among individuals with low BMI highlights the ethical link between nutrition and vaccine performance.
  • Public health ethics demand that vaccination be coupled with nutritional support to ensure equitable outcomes.
  • Indigenous Innovation - VPM1002’s single-dose, BCG-based design offers logistical simplicity and scalability — vital for India’s vast population.
  • Ethically, prioritizing indigenous solutions aligns with self-reliance and equitable global health.

How to move towards a Smarter TB Strategy?

  • TB is a slow-moving pandemic requiring sustained urgency.
  • India’s elimination goal must integrate:
    • Targeted vaccination for school-age children and household contacts.
    • Alignment with nutrition and preventive therapy programs.
    • Continued investment in diagnostics and case-based management. A combination of moderately effective vaccines across age groups may deliver immediate, tangible benefits.

What is the way forward?

  • The PreVenTB trial offers a light at the end of the tunnel for TB vaccine development.
  • India’s ethical and strategic challenge is to act decisively deploying tools that reduce severe disease today rather than waiting indefinitely for perfection.
  • A pragmatic, layered approach combining early detection, preventive therapy, vaccination, and nutrition can transform India’s TB control framework and bring the nation closer to its elimination goal.

 

Reference

The Hindu | India Needs Innovative strategies to eliminate TB

Login or Register to Post Comments
There are no reviews yet. Be the first one to review.

ARCHIVES

sidetext
Free UPSC Interview Guidance Programme
sidetext